CA2794377C — 2-oxo-dihydropyridine non-nucleoside reverse transcriptase inhibitors
Assigned to Merck Canada Inc · Expires 2015-06-16 · 11y expired
What this patent protects
Heteroaromatic compounds of Formula I: (I) are HIV reverse transcriptase inhibitors, wherein R1, R2, R3; R4 and R5 are defined herein. The compounds of Formula I and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis…
USPTO Abstract
Heteroaromatic compounds of Formula I: (I) are HIV reverse transcriptase inhibitors, wherein R1, R2, R3; R4 and R5 are defined herein. The compounds of Formula I and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
Drugs covered by this patent
- Pifeltro (DORAVIRINE) · Merck & Co.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.